| 王大鹏,夏庆欣.微 RNA?375对非小细胞肺癌脑转移的诊断价值[J].安徽医药,2020,24(1):38-41. |
| 微 RNA?375对非小细胞肺癌脑转移的诊断价值 |
| Diagnostic value of micro?RNA?375 in brain metastases of non?small cell lung cancer |
| |
| DOI：10.3969/j.issn.1009?6469.2020.01.010 |
| 中文关键词: 癌，非小细胞肺/诊断 肿瘤转移 肿瘤标记，生物学 预后 微 RNA ?375 |
| 英文关键词: Carcinoma,non?smallcelllung/diagnosis Neoplasmmetastasis Tumormarkers,biological Prognosis Micro?RNA?375 |
| 基金项目: |
|
| 摘要点击次数: 1703 |
| 全文下载次数: 527 |
| 中文摘要: |
| 目的分析微 RNA(miR)?375作为血清标志物诊断非小细胞肺癌( NSCLC)病人发生脑转移的临床价值。方法选取 2013年 2月至 2015年 2月郑州大学附属肿瘤医院收治的 185例初诊 NSCLC病人为研究对象，其中合并脑转移病人 78例纳入转移组，未发生脑转移病人 107例纳入未转移组，另选择 80例同期健康体检者为对照组，采用实时荧光定量 PCR检测受试者血清 miR?375表达水平，分析其表达水平对 NSCLC病人发生脑转移的诊断价值及与临床病理特征、预后的关系。结果转移组( 0.32±0.07)和未转移组( 0.73±0.18)血清 miR?375表达水平均显著低于对照组( 1.15±0.33)(P＜0.05)转移组血清 miR?375表达水平( 0.32±0.07)显著低于未转移组( 0.73±0.18)(P＜0.05)； NSCLC病人血清 miR?375表达水平与临床分，期、淋巴结转移显著相关( P＜0.05)； ROC曲线分析显示，血清 miR?375表达水平诊断 NSCLC病人发生脑转移的曲线下面积( AUC)为 0.975，灵敏度、特异度、准确率、阳性预测值、阴性预测值分别为 89.74%、94.39%、92.43%、92.11%、92.66%；多因素 Cox回归分析显示，临床分期、脑转移、血清 miR?375表达水平是影响 NSCLC病人预后的独立危险因素( P＜0.05)其他因素不是影响 NSCLC病人预后的重要因素( P＞0.05)。结论血清 miR?375表达水平下调与 NSCLC病人发生脑转移有，关，可能是诊断 NSCLC脑转移及 NSCLC病人预后判断的潜在生物标志物。 |
| 英文摘要: |
| Objective To analyze the clinical value of micro?RNA(miR)?375 as serum marker in the diagnosis of brain metasta? ses in patients with non?small cell lung cancer(NSCLC).Methods A total of 185 newly?diagnosed NSCLC patients admitted toAffiliated Tumor Hospital of Zhengzhou University from February 2013 to February 2015 were selected for the study.Among them， 78 patients with brain metastases were included in metastasis group，and 107 patients without brain metastases were included in non?metastasis group，and another 80 healthy examiners at the same period were set as control group.The expression level of serummiR?375 was detected by real?time fluorescent quantitative PCR.The diagnostic value of miR?375 expression level on brain metasta?ses in patients with NSCLC and its relationship with clinicopathological features and prognosis were analyzed.Results The expres?sion level of serum miR?375 in metastasis group and non?metastasis group was significantly lower than that in control group［( 0.32±0.07)vs.(0.73±0.18)vs.(1.15±0.33)］( P＜0.05)and the expression level of serum miR?375 in metastasis group was significantly lower than that in non?metastasis group(P＜0.05).，The expression level of serum miR?375 in patients with NSCLCwas significantly correlated with clinical stages and lymph node metastasis(P＜0.05).ROC curve analysis showed that the area un? der the curve(AUC)of serum miR?375 expression level for brain metastases in patients with NSCLC was 0.975，and the sensitivi? ty，specificity，accuracy rate，positive predictive value and negative predictive value were 89.74%，94.39%，92.43%，92.11% and 92.66%，respectively.Multivariate Cox regression analysis showed that clinical stages，brain metastases and serum miR?375 expres? sion level were independent risk factors for the prognosis of patients with NSCLC(P＜0.05)，and other factors were not important factors affecting the prognosis of patients with NSCLC(P＞0.05).Conclusion The down?regulation of serum miR?375 expression level is associated with brain metastases in patients with NSCLC，and it may be a potential biomarker for the diagnosis of NSCLCbrain metastases and judgement of prognosis in patients with NSCLC. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
